dc.contributor.author | Popat, S | |
dc.contributor.author | Liu, G | |
dc.contributor.author | Lu, S | |
dc.contributor.author | Song, G | |
dc.contributor.author | Ma, X | |
dc.contributor.author | Yang, JC-H | |
dc.date.accessioned | 2022-01-17T09:49:04Z | |
dc.date.available | 2022-01-17T09:49:04Z | |
dc.identifier.citation | Future oncology (London, England), 2021, 17 (32), pp. 4237 - 4247 | en_US |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4960 | |
dc.identifier.eissn | 1744-8301 | en_US |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2021-0608 | en_US |
dc.identifier.doi | 10.2217/fon-2021-0608 | |
dc.description.abstract | Crizotinib is highly efficacious and more tolerable than chemotherapy for ALK<sup>+</sup> non-small-cell lung cancer (NSCLC), but its progression-free survival benefit and intracranial efficacy have limitations. Head-to-head comparisons of next-generation ALK inhibitors in patients with ALK<sup>+</sup> NSCLC progressing on crizotinib will contribute toward optimizing survival. This international, Phase III, randomized, open-label study (ALTA-3) will therefore assign patients with locally advanced or metastatic ALK<sup>+</sup> NSCLC progressing on crizotinib to receive either brigatinib 180 mg qd (7-day lead-in at 90 mg qd) or alectinib 600 mg twice daily. The primary end point is progression-free survival as assessed by a blinded Independent Review Committee; the key secondary end point is overall survival. Clinical trial registration number: NCT03596866 (ClinicalTrials.gov). | en_US |
dc.format | Print-Electronic | en_US |
dc.format.extent | 4237 - 4247 | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.title | Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-07-22 | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.2217/fon-2021-0608 | en_US |
dc.relation.isPartOf | Future oncology (London, England) | en_US |
pubs.issue | 32 | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | en_US |
pubs.volume | 17 | en_US |
pubs.embargo.terms | Not known | en_US |
icr.researchteam | Thoracic Oncology | |
dc.contributor.icrauthor | Popat, Sanjay | |